GlassScriptPhysician profile
Lucia Chou
NPI 1114986130
$10,154.59
in general payments reported to CMS, 2019-2025
24 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,580 · 2020: $1,724 · 2021: $217 · 2022: $836 · 2023: $1,647 · 2024: $864 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Education: $60.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.15 |
| Education | $60.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,595.32 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $1,468.06 | 2019-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,222.71 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $939.05 | 2019-2024 | Vraylar, Qulipta |
| Amgen INC. | $861.98 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $624.65 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $616.71 | 2019-2023 | Verquvo |
| Novo Nordisk INC | $539.33 | 2019-2020 | |
| Astellas Pharma US INC | $349.12 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $339.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $218.17 | 2019 | |
| Sunovion Pharmaceuticals INC. | $211.52 | 2019 | |
| Amarin Pharma, INC. | $196.81 | 2019-2020 | |
| Abbott Laboratories | $161.93 | 2025 | Freestyle Libre 3 |
| Eisai INC. | $136.22 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $122.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $121.91 | 2019 | |
| Biogen, INC. | $119.90 | 2019 | |
| Akcea Therapeutics, INC. | $83.43 | 2019 | |
| Arbor Pharmaceuticals, INC. | $83.14 | 2020 | |
| Allergan, INC. | $72.82 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.04 | 2020 | |
| Glaxosmithkline, LLC. | $27.53 | 2020-2023 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucia Chou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.